A Cost-Consequence Model of Using the 21-Gene Assay to Identify Patients with Early-Stage Node-Positive Breast Cancer Who Benefit from Adjuvant Chemotherapy in the Netherlands

Martijn J. H. G. Simons, Peter M. Machielsen,Jelle A. Spoorendonk, Tim Ignacio, Pieter B. Drost, Tim Jacobs,Felix E. de Jongh

Journal of Medical Economics（2024）

Cited 0|Views0

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined